BC
BCAB
BioAtla, Inc.
$3.86
+8.43%
$6.4M
No data for this timeframe.
Vol
Market Cap$6.4M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$44.4K
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001826892·Prev Close $3.56
Recent Activity
May 31, 2026
Insider
Vasquez Christian surrendered for taxes 82 shares
Chief Financial Officer @ $3.93 ($322.26)
May 31, 2026
Insider
Sievers Eric surrendered for taxes 134 shares
Chief Medical Officer @ $3.93 ($526.62)
May 31, 2026
Insider
SHORT JAY M PHD surrendered for taxes 259 shares
Chief Executive Officer @ $3.93 ($1.0K)
May 13, 2026
earnings_calendar
BCAB Q1 2026 Earnings Scheduled — 2026-05-13
Apr 21, 2026
SEC
BioAtla reported Q4 2025 financial results with a net loss of $9.8 million, down from $14.9 million in the prior year, w
8-K — Impact 8/10
Mar 2, 2026
SEC
BioAtla is holding a special shareholder meeting to approve a merger with its wholly-owned subsidiary. The merger agreem
DEFA14A — Impact 4/10
Mar 2, 2026
Press
BioAtla announced a strategic review to explore asset sales, partnerships, or other transactions to maximize shareholder
Impact 7/10
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 13, 2025 | JMP Securities | DOWNGRADE | Market Outperform → Market Perform |
| Mar 31, 2025 | Citizens Capital Markets | MAINTAIN | Market Outperform → Market Outperform |
| Mar 31, 2025 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Nov 13, 2024 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Sep 16, 2024 | JMP Securities | REITERATE | Market Outperform → Market Outperform |
Latest Reports
BEARISH
8-K
8/10
BioAtla reported Q4 2025 financial results with a net loss of $9.8 million, down from $14.9 million in the prior year, w
Apr 21, 2026
NEUTRAL
DEFA14A
4/10
BioAtla is holding a special shareholder meeting to approve a merger with its wholly-owned subsidiary. The merger agreem
Mar 2, 2026
BEARISH
Press
7/10
BioAtla announced a strategic review to explore asset sales, partnerships, or other transactions to maximize shareholder
Mar 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MARSHALL WACE, LLP | $44.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 31, 2026 | Vasquez Christian | F | $322.26 |
| May 31, 2026 | Sievers Eric | F | $526.62 |
| May 31, 2026 | SHORT JAY | F | $1.0K |
| Mar 12, 2026 | SHORT JAY | F | $107.35 |
| Mar 11, 2026 | Vasquez Christian | F | $29.58 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
1 institutional holders with $44.4K total value (277,630 shares) as of 2026-Q1. Top holders: MARSHALL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 277,630 | $44.4K | 100.0% | — |
4 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 31, 2026 | Vasquez Christian | Chief Financial Officer | TAX W/H | 82 | $3.93 | $322.26 |
| May 31, 2026 | Sievers Eric | Chief Medical Officer | TAX W/H | 134 | $3.93 | $526.62 |
| May 31, 2026 | SHORT JAY M PHD | Chief Executive Officer | TAX W/H | 259 | $3.93 | $1.0K |
| Mar 12, 2026 | SHORT JAY M PHD | Chief Executive Officer | TAX W/H | 639 | $0.1680 | $107.35 |
| Mar 11, 2026 | Vasquez Christian | Chief Financial Officer | TAX W/H | 175 | $0.1690 | $29.58 |
| Mar 11, 2026 | Sievers Eric | Chief Medical Officer | TAX W/H | 360 | $0.1690 | $60.84 |
| Mar 11, 2026 | SHORT JAY M PHD | Chief Executive Officer | AWARD | 430,000 | — | — |
| Mar 10, 2026 | Sievers Eric | Chief Medical Officer | AWARD | 240,000 | — | — |
| Mar 10, 2026 | Vasquez Christian | Chief Financial Officer | AWARD | 240,000 | — | — |
| Feb 28, 2026 | Sievers Eric | Chief Medical Officer | TAX W/H | 3,140 | $0.2470 | $775.58 |
| Feb 28, 2026 | Vasquez Christian | Chief Financial Officer | TAX W/H | 1,802 | $0.2470 | $445.09 |
| Feb 28, 2026 | SHORT JAY M PHD | Chief Executive Officer | TAX W/H | 7,728 | $0.2470 | $1.9K |
| Feb 28, 2026 | WALDRON RICHARD A | Former Chief Financial Officer | TAX W/H | 2,729 | $0.2470 | $674.06 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
Historical analyst distribution (last covering-analyst action Aug 2025): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
9 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 8 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 13, 2025 | JMP Securities | DOWNGRADE | Market Outperform | Market Perform |
| Mar 31, 2025 | Citizens Capital Markets | MAINTAIN | Market Outperform | Market Outperform |
| Mar 31, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 13, 2024 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 16, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| May 23, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| May 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 28, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 27, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 5, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Nov 8, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 25, 2023 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 2, 2023 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 2, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Aug 2, 2023 | EF Hutton | REITERATE | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2023 | JMP Securities | REITERATE | Outperform | Outperform |
| May 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 12, 2023 | EF Hutton | REITERATE | Buy | Buy |
| Apr 17, 2023 | EF Hutton | MAINTAIN | — | Buy |
| Apr 3, 2023 | JP Morgan | MAINTAIN | — | Overweight |
| Mar 28, 2023 | BTIG | MAINTAIN | — | Buy |
| Mar 27, 2023 | JMP Securities | MAINTAIN | — | Outperform |
| Mar 24, 2023 | Credit Suisse | REITERATE | — | Neutral |
| Mar 24, 2023 | EF Hutton | REITERATE | — | Buy |
| Mar 24, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jan 5, 2023 | EF Hutton | INITIATE | — | Buy |
| Nov 4, 2022 | Credit Suisse | MAINTAIN | — | Neutral |
| Sep 15, 2022 | JMP Securities | INITIATE | — | Market Outperform |
| Aug 10, 2022 | Credit Suisse | MAINTAIN | — | Neutral |
| Aug 10, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 5, 2022 | Credit Suisse | DOWNGRADE | Outperform | Neutral |
| Mar 21, 2022 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jun 28, 2021 | Roth Capital | INITIATE | — | Buy |
| Mar 26, 2021 | BTIG | MAINTAIN | — | Buy |
| Jan 11, 2021 | Credit Suisse | INITIATE | — | Outperform |
| Jan 11, 2021 | Jefferies | INITIATE | — | Buy |
| Jan 11, 2021 | JP Morgan | INITIATE | — | Overweight |
| Jan 11, 2021 | BTIG | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$BCAB — Reading the Tea Leaves, a Reverse Merger Play
▲ 1
💬 0
⚡ 0.5
May 13, 2026
earnings_calendar
BCAB Q1 2026 Earnings Scheduled — 2026-05-13
May 4, 2026
earnings_calendar
BCAB Q1 2026 Earnings Scheduled — 2026-05-04
Apr 1, 2026
short_volume
Short Volume: BCAB — 55.6% short (1.0M / 1.8M)
Short: 994,693 | Exempt: 163,630 | TRF Vol: 1,790,486 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
earnings
BioAtla Announces Share Consolidation
<p align="justify">SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnolog
Mar 31, 2026
earnings
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
<p align="justify">SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused
Mar 25, 2026
short_volume
Short Volume: BCAB — 56.5% short (0.3M / 0.5M)
Short: 302,304 | Exempt: 22,786 | TRF Vol: 534,878 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
earnings_calendar
BCAB Q4 2025 Earnings After Market Close — 2026-03-19
Mar 2, 2026
activist
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
<p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnolog